CurrentAmbetter NevadaPolicy CP.MP.62

Hyperhidrosis Treatments

Customize your policy alerts

Sign up for Ambetter Nevada Policy CP.MP.62 alerts

Get alerted when Policy CP.MP.62 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy governs medical necessity and coverage criteria for iontophoresis, surgical excision of axillary sweat glands, endoscopic thoracic sympathectomy, and other treatments for hyperhidrosis.

Policy Summary

PayerAmbetter Nevada

PolicyHyperhidrosis Treatments

Policy CodePolicy CP.MP.62

Change TypeNo material change

Effective DateN/A

Last ReviewAug 1, 2026

Next Review DateN/A

Key ActionDocument the diagnosis, affected areas and severity, treatment failures, contraindications, and all modality-specific clinical criteria.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3Treatment modalities with stated medical-necessity criteria

>55 bpmRequired resting heart rate for ETS

<28Required BMI for ETS

<25 yearsUsual age for ETS request

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentAmbetter NevadaPolicy CP.MP.62

Hyperhidrosis Treatments

Customize your policy alerts

Sign up for Ambetter Nevada Policy CP.MP.62 alerts

Get alerted when Policy CP.MP.62 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy governs medical necessity and coverage criteria for iontophoresis, surgical excision of axillary sweat glands, endoscopic thoracic sympathectomy, and other treatments for hyperhidrosis.

Policy Summary

PayerAmbetter Nevada

PolicyHyperhidrosis Treatments

Policy CodePolicy CP.MP.62

Change TypeNo material change

Effective DateN/A

Last ReviewAug 1, 2026

Next Review DateN/A

Key ActionDocument the diagnosis, affected areas and severity, treatment failures, contraindications, and all modality-specific clinical criteria.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3Treatment modalities with stated medical-necessity criteria

>55 bpmRequired resting heart rate for ETS

<28Required BMI for ETS

<25 yearsUsual age for ETS request

Listed iontophoresis contraindications

08/26Most recent revision

Medical Necessity Criteria

Iontophoresis

Iontophoresis is medically necessary when ALL of the following are met:

Iontophoresis criteria

Diagnosis of primary hyperhidrosis
Impact or complication: Development of medical complications, such as skin maceration with secondary skin infections, or significant constant disruption of professional and/or social life because of excessive sweating
Examples include recurrent changing of clothes or effects on job or social function
Conservative management failure: Failed a trial of conservative management including adherent application of aluminum chloride hexahydrate (Drysol by prescription), or topical agents have resulted in a severe rash
No contraindications: Has none of the following contraindications: cardiac pacemaker, cardiac arrhythmias, pregnancy, metal implants depending on size and position, or epilepsy
Metal implants may divert the electric current depending on their size and position

Surgical excision of axillary sweat glands

Surgical excision of axillary sweat glands for axillary hyperhidrosis is medically necessary when ALL of the following are met:

Axillary sweat gland excision criteria

Iontophoresis criteria: Meets all iontophoresis criteria, including diagnosis of primary hyperhidrosis, qualifying medical complication or significant professional or social disruption, failed conservative management or severe rash from topical agents, and no listed contraindication
Severity: Has persistent and severe primary hyperhidrosis
Failed treatment
- Prior treatment options: Failed iontophoresis or a trial of botulinum toxin

Endoscopic thoracic sympathectomy

Endoscopic thoracic sympathectomy (ETS) for palmar or palmar and axillary hyperhidrosis is medically necessary when ALL of the following are met:

ETS criteria

Iontophoresis criteria: Meets all iontophoresis criteria, including diagnosis of primary hyperhidrosis, qualifying medical complication or significant professional or social disruption, failed conservative management or severe rash from topical agents, and no listed contraindication
Resting heart rate: Member or enrollee has a resting heart rate greater than 55 beats per minute> 55 beats per minute
Age and onset: Hyperhidrosis symptoms started at an early age and surgery is requested for a young member or enrolleeUsually symptom onset < 16 years and surgery request age < 25 years

Other hyperhidrosis treatments

All other treatments for hyperhidrosis are not supported by sufficient evidence.

Insufficient evidence: There is insufficient evidence in the published peer-reviewed literature to support all other treatments for hyperhidrosis, including, but not limited to, microwave therapy or liposuction as the sole method of removing axillary sweat glands

Iontophoresis is not medically necessary when the member has a cardiac pacemaker, cardiac arrhythmias, is pregnant, has metal implants that may divert the electric current depending on their size and position, or has epilepsy. These contraindications apply even when other iontophoresis eligibility requirements are documented.

Microwave therapy and liposuction as the sole method of removing axillary sweat glands are not supported by sufficient evidence in the published peer-reviewed literature and are not medically necessary under this policy.

All other treatments for hyperhidrosis that do not meet the policy's stated medical-necessity criteria are not supported by sufficient evidence in the published peer-reviewed literature. This includes microwave therapy and liposuction when used as the sole method of removing axillary sweat glands.

Coding and Clinical Thresholds

CPT CodesCPT

11450	Excision of skin and subcutaneous tissue for hidradenitis, axillary; with simple or intermediate repair.
11451	Excision of skin and subcutaneous tissue for hidradenitis, axillary; with complex repair.
15877*	Suction assisted lipectomy; trunk.
15878*	Suction assisted lipectomy; upper extremity.
32664	Thoracoscopy, surgical; with thoracic sympathectomy.
97024*	Application of a modality to 1 or more areas; diathermy (eg, microwave).
97033	Application of a modality to 1 or more areas; iontophoresis, each 15 minutes

ETS Resting Heart Rate

Required resting heart rate> 55 beats per minute

Applies toEndoscopic thoracic sympathectomy (ETS) for palmar or palmar and axillary hyperhidrosis

Eligibility contextThe member or enrollee must also meet the policy’s other ETS criteria

ETS Body Mass Index

Required body mass indexLess than 28

Applies toEndoscopic thoracic sympathectomy (ETS) eligibility

Policy wording

Documentation and Coverage Guidance

Note

Review Medicare Coverage Guidance

For Medicare members/enrollees, review all applicable Medicare National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and Medicare Coverage Articles before applying this policy’s criteria. Refer to the CMS website for additional information.

Review applicable NCDs, LCDs, and Medicare Coverage Articles before applying the policy criteria.

Step Therapy

Required Prior Treatment Before Excision

Before requesting coverage for surgical excision of axillary sweat glands, document persistent and severe primary hyperhidrosis, satisfaction of all iontophoresis criteria, and failure of required conservative treatment.

Document a diagnosis of primary hyperhidrosis and medical complications or significant constant disruption of professional and/or social life caused by excessive sweating.
Document failure of conservative management, including adherent application of prescription aluminum chloride hexahydrate (Drysol), or a severe rash from topical agents.
Document failure of one of the following: iontophoresis or a trial of botulinum toxin.

Clinical Background

Endoscopic thoracic sympathectomy (ETS) is an invasive procedure that interrupts the upper thoracic sympathetic chain by clipping, cauterization, or cutting to arrest hyperhidrosis symptoms. Because ETS may cause serious and irreversible compensatory sweating and other complications, it is considered a last-resort treatment when the applicable criteria are satisfied.

Key Definitions

Hyperhidrosis

DefinitionExcessive sweating beyond a level required to maintain normal body temperature

ClassificationHyperhidrosis may be classified as primary or secondary

Clinical significanceThe condition may ruin clothing, produce emotional distress, and lead to occupational disability

Primary Focal Hyperhidrosis

DefinitionIdiopathic excessive sweating induced by sympathetic hyperactivity in selected areas that is not associated with an underlying disease process

Typical locationsUnderarms, hands, and feet

Typical duration and presentation

Policy Summary

PayerAmbetter Nevada

PolicyHyperhidrosis Treatments

Policy CodePolicy CP.MP.62

Change TypeNo material change

Effective DateN/A

Last ReviewAug 1, 2026

Next Review DateN/A

Key ActionDocument the diagnosis, affected areas and severity, treatment failures, contraindications, and all modality-specific clinical criteria.

SourceLink

On This Page

BMI: Body mass index less than 28< 28

Sleep sweating: Reports no sweating during sleepNo sweating during sleep

Comorbidities: Member or enrollee has no significant comorbiditiesNone significant

Severity: Has persistent and severe primary hyperhidrosis

Failed treatment

Prior treatment options: Failed iontophoresis or a trial of botulinum toxin for predominantly axillary hyperhidrosis

Risk counseling: Member or enrollee has been counseled on the risks of the procedure

Body mass index < 28

ETS Symptom-Onset Age

Usual symptom-onset ageLess than 16 years

Policy wordingHyperhidrosis symptoms started at an early age, usually < 16 years

Applies toEndoscopic thoracic sympathectomy (ETS) eligibility

ETS Request Age

Usual age for surgery requestLess than 25 years

Policy wordingSurgery is requested for a young member or enrollee, usually < 25 years of age

Applies toEndoscopic thoracic sympathectomy (ETS) eligibility

Step Therapy

Required Prior Treatment Before ETS

Before requesting ETS for palmar or palmar and axillary hyperhidrosis, document that the member meets all iontophoresis criteria and has failed the applicable required prior treatment. For predominantly axillary hyperhidrosis, the failed botulinum toxin trial is an applicable alternative to failed iontophoresis.

Document failure of one of the following: iontophoresis or a trial of botulinum toxin for predominantly axillary hyperhidrosis.
The member must also have persistent and severe primary hyperhidrosis and meet the policy’s clinical thresholds and documentation requirements.

Documentation Required

Clinical Eligibility Documentation

Submit documentation establishing the diagnosis, affected treatment areas, severity, complications or functional impact, and conservative-treatment history. The record must support primary hyperhidrosis and the applicable procedure-specific criteria.

Diagnosis: primary hyperhidrosis.
Affected areas: axillary disease for sweat-gland excision; palmar or palmar and axillary disease for ETS.
Persistent and severe symptoms, with medical complications such as skin maceration and secondary skin infections, or significant constant disruption of professional and/or social life.
Conservative treatment history, including adherent prescription aluminum chloride hexahydrate (Drysol), intolerance or severe rash from topical agents, iontophoresis, and applicable botulinum toxin treatment.
Document the relevant contraindications and exclusions, including cardiac pacemaker, cardiac arrhythmias, pregnancy, metal implants that may divert electric current, and epilepsy.
For ETS, document counseling regarding procedural risks.

Documentation Required

ETS Supporting Documentation

ETS requests require supporting documentation for the clinical thresholds and exclusions in addition to diagnosis and prior-treatment records.

Resting heart rate > 55 beats per minute.
Symptoms began at an early age, usually before age 16, and surgery is requested for a young member/enrollee, usually under age 25.
Body mass index < 28.
No sweating during sleep.
No significant comorbidities.
Persistent and severe primary hyperhidrosis.
Failed iontophoresis or, for predominantly axillary hyperhidrosis, a trial of botulinum toxin.
Document counseling on the risks of ETS.

Denial Risk

Iontophoresis Criteria Not Met

Iontophoresis is not medically necessary when any required eligibility element is absent or a listed contraindication is present.

No documented diagnosis of primary hyperhidrosis.
No medical complication or significant constant disruption of professional and/or social life caused by excessive sweating.
No documented failure of conservative management, including adherent prescription aluminum chloride hexahydrate (Drysol), or no severe rash from topical agents when topical treatment was attempted.
Presence of a cardiac pacemaker, cardiac arrhythmias, pregnancy, a disqualifying metal implant, or epilepsy.

Denial Risk

Excision Criteria Not Met

Surgical excision of axillary sweat glands is not medically necessary when the member does not meet all iontophoresis criteria, does not have persistent and severe primary hyperhidrosis, or has not failed required prior treatment.

Iontophoresis criteria in I.A. through I.D. are not met.
Persistent and severe primary hyperhidrosis is not documented.
Failure of iontophoresis or a trial of botulinum toxin is not documented.

Denial Risk

ETS Criteria Not Met

ETS is not medically necessary when any required clinical threshold, exclusion, counseling requirement, or prior-treatment requirement is not satisfied.

Iontophoresis criteria in I.A. through I.D. are not met.
Resting heart rate is ≤ 55 beats per minute.
Symptoms did not begin at an early age, the requested surgery is not for a young member/enrollee as generally described, or the age history is undocumented.
Body mass index is ≥ 28.
Sweating occurs during sleep or the sleep-sweating history is undocumented.
Significant comorbidities are present.
Persistent and severe primary hyperhidrosis is not documented.
Failure of iontophoresis, or failure of a botulinum toxin trial for predominantly axillary hyperhidrosis, is not documented.
The member has not been counseled on procedural risks.

Denial Risk

Insufficient Evidence for Other Treatments

There is insufficient evidence in the published peer-reviewed literature to support treatments outside the stated coverage criteria. Requests for these treatments should not be approved under this policy without applicable coverage authority.

Microwave therapy is not supported under the policy.
Liposuction as the sole method of removing axillary sweat glands is not supported under the policy.
Other treatments for hyperhidrosis not meeting the policy’s stated criteria are subject to denial for insufficient evidence.

Visible, excessive sweating of at least six months’ duration without apparent cause

Secondary Hyperhidrosis

DefinitionHyperhidrosis resulting from drugs or an underlying disease or condition

Typical distributionUsually generalized or craniofacial sweating

Examples of causesTricyclic antidepressants, selective serotonin reuptake inhibitors, febrile diseases, diabetes mellitus, or menopause

Endoscopic Thoracic Sympathectomy (ETS)

DefinitionAn invasive procedure intended to arrest the symptoms of hyperhidrosis

How it worksInterrupts the upper thoracic sympathetic chain through clipping, cauterization, or cutting

Clinical considerationIt is considered a last resort because of potentially serious, irreversible compensatory sweating and other effects